Abstract
MPM is a highly aggressive pleural tumor associated with asbestos exposure and with limited survival despite systemic therapy. Recently immunotherapy have demonstrated survival benefit in first line. Currently there is no universally accepted surgical therapy for MPM and it remains unclear whether cytoreductive surgery prolongs survival. Some reports on selected patients demonstrated that, at the progressive disease, second round surgery is an effective strategy with minimal morbidity and promising survival rates.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
